P348: MRK-560 AND DEXAMETHASONE ARE SYNERGISTIC IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Main Authors: | C. Vandersmissen, C. Prieto Fernàndez, O. Gielen, K. Jacobs, I. Govaerts, J. Maertens, H. Segers, J. Cools |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844280.15661.45 |
Similar Items
-
Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
by: Delphine Verbeke, et al.
Published: (2019-12-01) -
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia
by: Inge Govaerts, et al.
Published: (2021-06-01) -
Molecular basis for isoform-selective inhibition of presenilin-1 by MRK-560
by: Xuefei Guo, et al.
Published: (2022-10-01) -
MRK
by: 361332 Abd. Halim Lazim
Published: (2000) -
Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing
by: Sarah Meyers, et al.
Published: (2022-04-01)